Appendix C

Speaker and Moderator Biographical Sketches

Jo Ivey Boufford, M.D., is Co-Chair of the Forum on Public–Private Partnerships for Global Health and Safety and immediate past President of The New York Academy of Medicine. She is a Clinical Professor of Global Public Health at the College of Global Public Health at New York University, where she is also Professor of Public Service, Health Policy, and Management at the Robert F. Wagner Graduate School of Public Service and Clinical Professor of Pediatrics at the New York University School of Medicine. She served as Dean of the Robert F. Wagner Graduate School of Public Service at New York University from June 1997 to November 2002. Prior to that, she served as Principal Deputy Assistant Secretary for Health in the U.S. Department of Health and Human Services (HHS) from November 1993 to January 1997, and as Acting Assistant Secretary from January 1997 to May 1997. While at HHS, she was the U.S. representative on the Executive Board of the World Health Organization (WHO) from 1994 to 1997. She served in a variety of senior positions and as President of the New York City Health and Hospitals Corporation (HHC), the largest municipal system in the United States, from December 1985 until October 1989. Dr. Boufford was awarded a Robert Wood Johnson Health Policy Fellowship at the Institute of Medicine in Washington, DC, for 1979–1980. She currently serves on the boards of the United Hospital Fund and the Health Effects Institute. She was elected to membership in the National Academy of Medicine in 1992 and served on the National Academies of Sciences, Engineering, and Medicine’s Board on Global Health and Board on African Science Academy Development.

She served two 4-year terms as the Foreign Secretary of the National Academy of Medicine between 2010 and 2014 and was elected to membership for the National Academy of Public Administration in 2015. She received Honorary Doctorate of Science degrees from the State University of New York, Brooklyn (1992), New York Medical College (2007), Pace University (2011), and Toledo University (2012). She has been a Fellow of The New York Academy of Medicine since 1988 and a Trustee since 2004. Dr. Boufford attended Wellesley College for 2 years and received her B.A. (Psychology) magna cum laude from the University of Michigan” and her M.D., with distinction, from the University of Michigan Medical School. She is board-certified in pediatrics.

Douglas M. Brooks, M.S.W., a social worker, began his career in HIV/AIDS with his work for the Provincetown AIDS Support Group. He went on to become the Senior Vice President for Community, Health, and Public Policy at the Justice Resource Institute (JRI), a regional health and human service agency based in Massachusetts. He also previously served as Executive Director of the Sidney Borum Jr. Health Center. He also served as Chair of the Board of Trustees of AIDS United in Washington, DC. In 2010, Mr. Brooks was appointed to the Presidential Advisory Council on HIV/AIDS (PACHA) and subsequently named that body’s liaison to the Centers for Disease Control and Prevention/Health Resources and Services Administration Advisory Committee. In 2014, he was appointed to be Director of the White House Office of National AIDS Policy. In 2015, Mr. Brooks spearheaded an update to the National HIV/AIDS Strategy, which is a 5-year plan that guides priorities and principles for our nation in our response to HIV. Mr. Brooks is an openly gay man living with HIV. During his time as director of the Office of National AIDS Policy, he focused on turning attention to populations of people most affected by the epidemic—such as gay and bisexual men, especially those of color, black women, transgender men and women, and people living in the southern United States. He supported the widespread scale up of PrEP (pre-exposure prophylaxis), and included this in the updated strategy as a key way to reduce new infections in the United States. In May 2016, Mr. Brooks started in the newly created role of Senior Director for Community Engagement at Gilead Sciences.

Anthony Brown, J.D., M.B.A., is Senior Legal Counsel with Gavi, the Vaccine Alliance. Since joining Gavi in 2005, Mr. Brown has been instrumental in a number of corporate initiatives, including the setup and continued operation of two major multistakeholder financing schemes, the International Finance Facility for Immunisation and the Advance Market Commitment for Pneumococcal Vaccine to provide long-term

guaranteed funding to Gavi and incentivize manufacturers to develop a pneumococcal vaccine for Gavi countries respectively. He has advised on and negotiated multiple private partnership engagements, such as Gavi’s 2016 Advance Purchase Commitment for an Ebola vaccine. He also co-led Gavi’s 2008 Governance transition from three separate entities into a Swiss international organization. Besides his corporate and financing expertise, Mr. Brown advises on issues across Gavi’s spectrum, including governance, country programs, regulatory, insurance, and personnel-related matters. From 2015 to 2016, on a secondment, Mr. Brown was Acting General Counsel/Senior Legal Officer with the CGIAR (Consultative Group on International Agricultural Research) System Organization, a global agricultural research partnership, where he served on the governance transition team as the organization underwent a major restructuring. Afterward, he led the development of the organization’s new partnership financing agreements. Prior to Gavi, Mr. Brown worked in Washington, DC, with the law firm of Williams & Connolly. Prior to graduate school, Mr. Brown worked in the New York office of the international consulting firm Booz Allen Hamilton. Mr. Brown is a graduate of Columbia College and earned his J.D. from the University of Pennsylvania Law School and his M.B.A. from the Wharton School.

Steve Davis, J.D., M.A., president and CEO of PATH, combines extensive experience as a technology business leader, global health advocate, and social innovator to accelerate great ideas and bring lifesaving solutions to scale. Prior to joining PATH in 2012, he served as director of Social Innovation at McKinsey & Company, CEO of internet pioneer and global digital media firm Corbis, and interim director of the Infectious Disease Research Institute. He also practiced law at the international law firm K&L Gates. Earlier, he worked extensively on refugee programs and policies, as well as Chinese politics and law. Mr. Davis is a lecturer on social innovation at the Stanford Graduate School of Business. He currently is a member of the Council on Foreign Relations, serves on the boards of InterAction and Challenge Seattle, and sits on several advisory groups, including as a trustee of the World Economic Forum’s Global Health Challenge, on the stakeholder advisory panel for the global insurance and asset management firm AXA, and on the advisory board for Medtronics Labs. Mr. Davis earned his B.A. from Princeton University, his M.A. in Chinese studies from the University of Washington, and his law degree from Columbia University. He also studied at Beijing University.

Mark Dybul, M.D., is a professor in the Department of Medicine at Georgetown University Medical Center and the Faculty Director of the Center for Global Health and Quality. Dr. Dybul has worked on HIV and

public health for more than 25 years as a clinician, scientist, teacher, and administrator, and most recently as the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria. After graduating from Georgetown Medical School in Washington DC, Dr. Dybul joined the National Institute of Allergy and Infectious Diseases as a research fellow under director Dr. Anthony Fauci, where he conducted basic and clinical studies on HIV virology, immunology, and treatment optimization, including the first randomized controlled trial with combination antiretroviral therapy in Africa. Dr. Dybul was one of the founding architects in the formation of The U.S. President’s Emergency Plan for AIDS Relief, better known as PEPFAR. After serving as Chief Medical Officer and Assistant, Deputy, and Acting Director, he was appointed as its leader in 2006, becoming the U.S. Global AIDS Coordinator, with the rank of Ambassador at the level of an Assistant Secretary of State. He served until early 2009. Dr. Dybul has written extensively in scientific and policy literature and has received several Honorary Degrees and awards, including a Doctor of Science, Honoris Causa, from Georgetown University.

Kevin Etter, who has worked for more than three decades with UPS (United Parcel Service), is an internationally recognized thought leader in the field of logistics and supply chain service innovation. A few of his accomplishments to date include large aircraft fleet acquisition and integration projects; development of new services built through focusing on strategic mergers and acquisition activities; new service ideas and innovation for the pharmaceutical, medical device, and health products supply chain and security; and new ways of thinking about corporate social responsibility. Mr. Etter is a strong voice and advocate in the world of community service and corporate philanthropy, active both at home, in Europe, and at UPS. A recent partnership for the UPS Foundation had him seconded (executive on loan) to Gavi, the Vaccine Alliance, in Geneva, Switzerland. There, Mr. Etter played a key role in advising, consulting, and developing solutions supporting Gavi’s Supply Chain Strategy. Mr. Etter pioneered innovative models for public–private partnerships with Gavi, United Nations organizations, and other international nongovernmental organizations. Mr. Etter has recently presented a TED Talk titled “I am the Donation” that features his work with Gavi and highlights the opportunity that business communities have in moving beyond checkbook philanthropy to impact real change in our world today.

Clarion Johnson, M.D., Co-Chair of the Forum on Public–Private Partnerships for Global Health and Safety, served as Global Medical Director of ExxonMobil Corporation until his retirement in 2013. Currently, Dr. Johnson is a consultant to ExxonMobil, the immediate past Chair of

The Joint Commission’s International and Resource Boards, and a member of the Yale School of Public Health Leadership Council. He serves on several boards including the Bon Secours Hospital System, the Advisory Board of the Yale School of Public Health, and the Board of the Milbank Memorial Fund. Dr. Johnson previously served on the U.S. National Academies’ Board on Global Health. Dr. Johnson also has a U.S. Department of Health and Human Services Secretary appointment to the National Institute for Occupational Safety and Health Advisory Board and was a member of the Virginia Governor’s Task Force on Health reform and co-chair of the Insurance Reform Task Force. He is the past chair of Virginia Health Care Foundation and of the Board of City Lights Charter School in Washington, DC. He served as advisor and lecturer in the Harvard Medical School’s department of continuing education “Global Clinic Course” from 2005 to 2008. In 2013 he received the President’s Award from the Oil and International Petroleum Industry Environment Conservation Association (IPIECA) and Oil and Gas Producers (OGP) for contributions to health, and in 2012 he was the recipient of the Society of Petroleum Engineers (SPE) Award for Health, Safety, Security, Environment, and Social Responsibility. In 2011, he received a medal from the French Army’s Institut de Recherche Biomédicale for Project Tetrapole: a public–private partnership in malaria research. Dr. Johnson is a graduate of Sarah Lawrence College and member of its Board of Trustees and of the Yale School of Medicine. While on active duty in the U.S. Army, he also trained as a microwave researcher at Walter Reed Army Institute of Research. He is board-certified in internal medicine, cardiology, and occupational medicine.

Lauren A. Marks, J.D., is the Director of Private-Sector Engagement in the Office of the U.S. Global AIDS Coordinator and Health Diplomacy (S/GAC), which leads the implementation of The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). Ms. Marks leads the Private-Sector Engagement Team to support the development, implementation, and evaluation of policies, interventions, and strategies for public–private partnerships (PPPs) by working closely with country teams, implementation partners, private-sector organizations, foundations, and multilateral institutions. Ms. Marks comes to S/GAC from the private sector, having managed the HIV/AIDS portfolio for Johnson & Johnson’s Corporate Contributions group. Prior to joining Johnson & Johnson, Ms. Marks served as the Health Program/Public–Private Partnership Advisor at the U.S. Agency for International Development (USAID)/South Africa, where she built several successful PPPs between the U.S. government, the private sector, and nongovernmental organizations. Ms. Marks also worked at USAID in Washington, DC, in the Bureau for Global Health, where she

provided technical support to USAID missions in several African and Asian countries. Prior to USAID, Ms. Marks was a corporate attorney at Nixon Peabody LLP in New York. She has a law degree from Georgetown University and a B.A. from Duke University.

Sonal Mehta, M.S.W., I.M.P.M., advanced to the level of Chief Executive of Alliance India in October 2016 after serving in the capacity of Director of Programmes and Policy in the organization for 9 years. With three decades of experience in sexual health and development, Ms. Mehta guides Alliance India’s mission of community action for ending AIDS with programmatic experience and management smartness. Before joining Alliance India, Ms. Mehta was Challenge Fund Manager in the United Kingdom’s Department for International Development program that led to many path-breaking interventions in India, including bringing oral substitution therapy for people who inject drugs. Prior to that she worked with organizations in India, including NACO (National Aids Control Organization), Gujarat SACS (State AIDS Control Society), CHETNA (Centre for Health Education, Training and Nutrition Awareness), and SEWA (Self Employed Women’s Association), as well as with the Pacific Institute of Women’s Health in Los Angeles, California. Ms. Mehta has an M.S.W. from the Faculty of Social Work, Vadodara, Gujarat. In a stride to continue learning, she completed her International Masters in Practicing Management (I.M.P.M.) from McGill University and is pursuing a master’s in Science in International Management from Lancaster University, United Kingdom.

Kenneth Miller, J.D., is Associate General Counsel at the Bill & Melinda Gates Foundation, where he provides legal advice to the foundation’s Global Health Division to help structure and negotiate agreements for innovative charitable investments, including grants, contracts, and program-related investments to develop and deliver vaccines, drugs, and diagnostics to people most in need. Before joining the foundation in 2015, Mr. Miller was a partner in the technology transactions group at Perkins Coie LLP, an international law firm based in Seattle, where he represented leading-edge technology companies in complex intellectual property and commercial transactions.

John T. Monahan, J.D., is a Senior Advisor for Global Initiatives to Georgetown University’s President John J. DeGioia and a Senior Fellow at Georgetown’s McCourt School of Public Policy. In his current position, he advances university-wide initiatives in global health and related areas; chairs a senior-level committee examining the future of Georgetown’s masters programs in international development; co-chairs the Lancet--

Georgetown Commission on Global Health and Law; and has been teaching global health courses in Georgetown’s foreign service, law, and nursing schools. Over the course of his distinguished career, Mr. Monahan has played multiple leadership roles in government, diplomacy, politics, philanthropy, and academia at the global, national, state, and local levels. He has focused on managing complex health, social service, and development issues and programs affecting low-income and vulnerable populations in the United States and abroad. From 2010 to 2014, Mr. Monahan served as Special Advisor for Global Health Partnerships at the U.S. Department of State. Under the leadership of Secretaries Clinton and Kerry, he was the chief architect of the Obama administration’s successful strategy for reforming the operations and replenishing the finances of the Global Fund to Fight AIDS, Tuberculosis and Malaria, an innovative public–private partnership based in Switzerland. He served as the U.S. government’s representative on the Global Fund’s board; a member of the board’s Comprehensive Reform Working Group; and Vice-Chair of the board’s Finance and Operational Performance Committee. In 2009–2010, he was Director of the Office of Global Health Affairs at the U.S. Department of Health and Human Services (HHS) and served as a primary liaison to the World Health Organization’s leadership during the H1N1 influenza pandemic. He also served as Counselor to the Secretary of HHS and represented the Department on the White House–led interagency task force implementing the stimulus legislation in 2009. Mr. Monahan also has extensive experience with domestic public policy issues. From 2000 to 2007, he served as Senior Fellow at the Annie E. Casey Foundation, a philanthropy dedicated to low-income children in the United States. He advised the Foundation’s senior leadership on federal policy issues; managed its relationship with Living Cities, a public–private partnership devoted to U.S. community development; and supported its use and advocacy of loan guarantees and innovative program-related investment strategies. During the Clinton administration, Mr. Monahan served as Director of Intergovernmental Affairs at HHS, where he represented the department in negotiations with governors and state officials regarding scores of Medicaid and welfare demonstration waivers; and as Principal Deputy Assistant Secretary for Children and Families, in which he was responsible for assisting in implementation of federal welfare reform. In his varied career, he has also served as the founding Executive Director of Georgetown’s O’Neill Institute for National and Global Health Law; Legal Counsel to U.S. Senator David Pryor; Law Clerk to U.S. District Court Judge John Grady; and is a veteran of numerous political races, including the Mondale and Clinton presidential campaigns. A member of the Council on Foreign Relations, he serves on the Advisory Committee of the Fogarty International Center at the National Institutes of Health

and on the boards of the Lever Fund and the U.S. Committee for Refugees and Immigrants. Mr. Monahan holds bachelor’s and law degrees cum laude from Georgetown University.

C. D. Mote, Jr., Ph.D., M.S., is president of the National Academy of Engineering (NAE) and Regents Professor on leave from the University of Maryland. He was president of the University of Maryland for 12 years and was on the University of California, Berkeley, faculty for 31 years, where he held an endowed chair in mechanical systems, chaired the Mechanical Engineering Department, and served as vice chancellor. As president of the NAE, he is committed to ensuring highly competitive talent in the U.S. engineering workforce, facilitating public understanding of engineering, demonstrating how engineering creates a better quality of life, and engaging the academy in global engineering issues in support of national interests. A highlight of global engineering engagement is the promotion of the NAE’s 14 Grand Challenges for Engineering from 2008, whose solutions are goals to achieve the vision “Continuation of life on the planet, making our world more sustainable, safe, healthy, and joyful.” Dr. Mote is internationally recognized for his research on the dynamics of gyroscopic systems and the biomechanics of snow skiing. He has produced more than 300 publications and is a fellow of the American Academy of Arts and Sciences, American Academy of Mechanics, American Association for the Advancement of Science, and Acoustical Society of America, and an honorary fellow of the American Society of Mechanical Engineers (ASME). He is a Foreign Member of the Chinese Academy of Engineering and an Honorary Academician of the Academia Sinica. He is the 2005 recipient of the NAE Founders Award and the 2011 recipient of the ASME Medal in recognition of his comprehensive body of work on the dynamics of moving flexible structures and his leadership in academia.

Nina Nathani, J.D., is a founding partner of Matalon & Nathani, LLP. She has devoted nearly 20 years of her career to providing legal advice and counsel to nonprofit organizations of all sizes who work across different sectors and with support from a variety of U.S. and foreign donors, both public and private. Her expertise extends to traditional nonprofit governance, operations, and compliance matters, including establishment of nonprofit corporations, applications for tax-exempt status, corporate governance and ethics, grants and contracts, fundraising (including charitable solicitations), gift acceptance policies, procurement of goods and services, intellectual property, commercial leases and other agreements, lobbying, and employment and consultancy agreements. She also has significant expertise in advising global nongovernmental organizations (NGOs) on matters particular to their overseas operations, including establishing

branch offices, working with local NGOs, and monitoring and evaluation of subrecipients and subcontractors, as well as the formation, governance, and management of collaborative arrangements among NGOs, commercial companies, and governmental and multilateral institutions, with a focus on public–private partnerships. Her early legal career included several years working as an associate at Akin Gump Strauss Hauer & Feld LLP and Steptoe & Johnson LLP and as an Attorney Advisor in the USAID Office of General Counsel.

Cate O’Kane knows that partnerships can make change happen, be that in Europe, Asia, Africa, or her current base in the United States. With an innate curiosity about people and culture, she has successfully led multidisciplinary and multinational teams and developed an understanding of the finer nuances of partnership. As founder of partnership consultancy &co, Ms. O’Kane now develops strategic partnerships that ensure success for all parties involved, be that a multinational company, a government agency, or a nonprofit implementer. Previously, Ms. O’Kane was Director of Corporate Partnerships & Philanthropy at PSI in Washington, DC, where she led the development of philanthropic, social responsibility, and shared value partnerships, integrating the worlds of purpose and profit to deliver win-win opportunities. During her tenure at PSI, corporate partnerships quadrupled in number, and revenue from partnerships grew 600 percent. She emphasized the value of partnerships to provide not only financial investment at a country level but also as a means of knowledge sharing and individual capacity development through fellowships and joint thought leadership. Prior to her time at PSI’s headquarters, Ms. O’Kane was the Technical Services Director at PSI/Botswana where she led the platform’s marketing, communications, and research programs across a multitude of HIV/AIDS interventions. In building partnerships across sectors from defense to health to communications, she produced the first Botswana edutainment television series Morwalela, featuring the lives of Batswana living with HIV, and developed a camouflage condom in partnership with the Botswana Defense Force. She spent her time before PSI working in Europe and Asia for 16 years in advertising and communications roles. Her last role in industry was as Director of J. Walter Thompson’s North East Asia team, based in Shanghai and working to expand market share for companies in this dynamic region. She is a member of the Devex Strategic Advisory Council, working across sectors to encourage stronger partnership practices, and was a founding member of the INGO collective within FSG’s Shared Value Initiative. She has spoken on the development, role, and management of partnerships for impact at USAID, FSG, Devex, SOCAP (Social Capital Markets), United Nations Global Compact, and PYXERA Global events.

Muhammad Ali Pate, M.D., M.B.A., is CEO of Big Win Philanthropy. Dr. Pate was Minister of State for Health of the Federal Republic of Nigeria from July 2011 to July 2013. He led the successful Presidential Task Force on Polio Eradication in Nigeria and developed the results-based initiative Save One Million Lives. From 2013 to 2015, Dr. Pate was visiting Professor at Duke University’s Global Health Institute. Previously, Dr. Pate served as the Chief Executive of Nigeria’s Primary Health Care Development Agency and worked for several years at the World Bank Group in Washington, DC. He is a founding Co-Chair of the board of the Private-Sector Health Alliance in Nigeria and serves on Merck’s Advisory Board for Merck for Mothers, Harvard’s Defeating Malaria Initiative, the FHI 360 Advisory Board, and the World Economic Forum Global Agenda Council on Demographic Dynamics. He received the Geneva Health Forum Award in 2014 and the Harvard Health Leadership Award in 2012. Dr. Pate is certified by the American Board of Internal Medicine in the specialty of Internal Medicine with a subspecialty in infectious diseases. He also holds an M.B.A. in Health Sector Management Concentration.

Regina Rabinovich, M.D., M.P.H., is the ExxonMobil Malaria Scholar in Residence at Harvard University and International Scholar at ISGLOBAL at the University of Barcelona. She has more than 25 years of experience in global health across research, public health, and philanthropic sectors, with a focus on strategy, global health product development, and the introduction and scale up of tools and strategies resulting in impact on endemic populations. From 2003 to 2012, Dr. Rabinovich served as Director of the Infectious Diseases division at the Bill & Melinda Gates Foundation, overseeing the development and implementation of strategies for the prevention, treatment, and control of infectious diseases of particular relevance to malaria, pneumonia, diarrhea, and neglected infectious diseases. Dr. Rabinovich has served as Chief of the Clinical and Regulatory Affairs Branch at the U.S. National Institute of Allergy and Infectious Diseases (NIAID), focusing on the development and evaluation of vaccines through a network of U.S. clinical research units. She participated in the Children’s Vaccine Initiative, a global effort to prevent infectious diseases in children in the developing world. In 1999, Dr. Rabinovich became director of the PATH Malaria Vaccine Initiative, a project funded by the Bill & Melinda Gates Foundation to advance efforts to develop promising malaria vaccine candidates. She serves on the boards of AERAS, a nonprofit biotech company focused on development of vaccines for tuberculosis; the Sabin Vaccine Institute; and the Catholic Medical Mission Board. She is the President-Elect of the American Society of Tropical Medicine and Hygiene. Dr. Rabinovich holds a medical degree from Southern

Illinois University and a Master’s of Public Health degree from the University of North Carolina.

Michael R. Reich, Ph.D., is the Taro Takemi Research Professor of International Health Policy at the Harvard T.H. Chan School of Public Health. He received his Ph.D. in political science from Yale University in 1981 and has been a member of the Harvard faculty since 1983. Dr. Reich has longstanding research interests in the political economy of pharmaceutical policy, access to medicines, and public–private partnerships, and has published extensively on these topics. Several publications are particularly relevant to this Workshop. In 2002, he edited a book called Public–Private Partnerships for Public Health (Harvard University Press). He co-authored the landmark textbook on health systems, Getting Health Reform Right: A Guide to Improving Performance and Equity (Oxford University Press, 2004, with M. J. Roberts, W. C. Hsiao, and P. Berman). In 2008, Dr. Reich published a book with Laura J. Frost, Access: How do Good Health Technologies Get to Poor People in Poor Countries? (Harvard University Press, 2008). Many of his publications are available on his Harvard faculty website. He was a member of the Lancet Commission on Essential Medicines Policies, which published its report in fall 2016. He is also a founding Editor-in-Chief of the new journal Health Systems & Reform, now in its fourth year.

Peter Rockers, Sc.D., is an Assistant Professor in the Department of Global Health at the Boston University School of Public Health, where he is also the Director of the Monitoring and Evaluation certificate program. His research primarily focuses on evaluating interventions and policies that aim to strengthen health systems in developing countries. He is co-principal investigator for a project developing a framework for evaluating pharmaceutical industry-led access to medicines programs. He is also co-investigator for a cluster randomized trial in Kenya evaluating the impact of Novartis Access on the availability and price of noncommunicable disease medicines. Dr. Rockers received a Doctor of Science degree from the Harvard T.H. Chan School of Public Health.

Danielle Rollmann, M.P.A., leads Access Priorities within Pfizer’s Global Policy team. She drives significant cross-functional initiatives to enhance patient access to medicines, including supporting Pfizer’s engagement in Access Accelerated, a multicompany initiative to address the full spectrum of access barriers to medicines for noncommunicable diseases (NCDs) in lower-income countries, and providing policy support for innovative financing and reimbursement approaches. Ms. Rollmann was previously a partner in the Global Health Practice of Booz & Company, a strategic management consulting firm. She served clients in the pharmaceutical,

diagnostics, consumer health, and other life sciences industries for 17 years, as an advisor on commercial innovation, growth and marketing strategy, and business transformation.

BT Slingsby, M.D., Ph.D., M.P.H., is the founding CEO and Executive Director of the Global Health Innovative Technology Fund (GHIT Fund). The GHIT Fund is a public–private partnership in Japan between the government of Japan (Ministry of Foreign Affairs and Ministry of Health, Labour and Welfare); 16 life science companies (Astellas, Chugai, Daiichi Sankyo, Eisai, Fujifilm, GlaxoSmithKline, Johnson & Johnson, Kyowa Hakko Kirin, Merck, Mitsubishi Tanabe, Nipro, Otsuka, Shionogi, Sumitomo Dainippon, Sysmex, and Takeda), the Bill & Melinda Gates Foundation; Wellcome Trust; and the United Nations Development Programme. Launched in April 2013 with a commitment of more than $100 million, GHIT has grown to manage more than $350 million with a portfolio of more than 50 investments in the research and development of novel Japanese innovations for global health. The combination of Japan’s government and its pharmaceutical industry—the second largest in the world—brings a powerful engine of knowledge and innovation to the development of medications for the developing world. Prior to the GHIT Fund, he was global head for access and strategy for the developing world at Eisai Co. & Ltd. Dr. Slingsby is adjunct professor at Kyoto University Graduate School of Medicine and the University of Tokyo Graduate School of Medicine and has published more than 50 peer-reviewed articles in English and Japanese in journals including Journal of General Internal Medicine, Journal of Public Health, and The Lancet. He graduated from Brown University, earned his Masters and Doctorate from Kyoto University and the University of Tokyo, and received his Medical Doctorate from The George Washington University.

Jeffrey L. Sturchio, Ph.D., is President and CEO at Rabin Martin, a global health strategy consulting firm, and former President and CEO of the Global Health Council. Before joining the Council in 2009, Dr. Sturchio was vice president of Corporate Responsibility at Merck & Co., Inc., president of the Merck Company Foundation, and chairman of the U.S. Corporate Council on Africa (CCA), whose 160 member companies represent some 85 percent of total U.S. private-sector investment in Africa. While at Merck & Co., Inc., he was a leader of the company’s global HIV/AIDS policy for more than a decade and was centrally involved in the UN/Industry Accelerating Access Initiative established in 2000 to help improve HIV/AIDS care and treatment in the developing world. He was a member of the board of the African Comprehensive HIV/AIDS Partnerships in Botswana (2005–2009) and a member of the private-sector delegation to the board of the Global Fund to Fight AIDS, Tuberculosis and Malaria

(2002–2008). He is chairman of the Corporate Council on Africa, chairman of the BroadReach Institute for Training and Education, and a member of the boards of ACHAP (African Comprehensive HIV/AIDS Partnerships), the Science History Institute, and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria. Dr. Sturchio is also currently a visiting scholar at the Institute for Applied Economics, Global Health and the Study of Business Enterprise at Johns Hopkins University; Senior Associate at the Center for Strategic and International Studies; a principal of the Modernizing Foreign Assistance Network; Fellow of the American Association for the Advancement of Science; a member of the Council on Foreign Relations and the Arthur W. Page Society; and an advisor to amfAR, Intrahealth International, and the Partnership for Quality Medical Donations. He received an A.B. in history from Princeton University and a Ph.D. in the history and sociology of science from the University of Pennsylvania. His publications include Noncommunicable Diseases in the Developing World: Addressing Global Gaps in Policy and Research (edited with L. Galambos, Johns Hopkins University Press, 2013).

Valerie Wenderoth, J.D., is an attorney-advisor within the U.S. Department of State’s Office of the Legal Adviser responsible for the entire area of financial and appropriations law (other than foreign assistance), as well as other highly specialized areas, such as financial management and reporting, fiscal irregularities and contingencies, public–private partnerships, and eGovernment. Prior to joining the U.S. Department of State in November 2007, Ms. Wenderoth held various positions within the Office of the General Counsel for the Department of the Navy, including Deputy Assistant General Counsel for Research, Development, and Acquisition and Deputy Assistant General Counsel for Financial Management and Comptroller. Ms. Wenderoth began her law career as an assistant counsel at the Naval Sea Systems Command, focusing on ship building and repair claims and litigation. Ms. Wenderoth is a graduate of the University of Colorado Boulder, where she earned a B.A. in History and German. She earned her J.D. from the University of Denver College of Law.

Veronika J. Wirtz, M.Sc., Ph.D., is an Associate Professor in the Department of Global Health at the Boston University School of Public Health, where she is also Director of the World Health Organization Collaborating Center in Pharmaceutical Policy. Her research interests include the role of the private sector to promote equitable access and efficient use of medicines in low- and middle-income countries, medicines price analysis, generic medicines policies, and access to medicines for noncommunicable diseases. Between 2014 and 2016 she was the Co-Chair of The Lancet Commission on Essential Medicine Policies, which published its report

Essential Medicines for Universal Health Coverage in Fall 2016. She has worked as a technical advisor for various international organizations, among them the World Health Organization; the Pan American Health Organization; the Global Fund to Fight AIDS, Tuberculosis and Malaria; the Bill & Melinda Gates Foundation; and Alliance for Health Systems and Policy Research. She is a Visiting Professor of the National Institute of Public Health (INSP), Mexico, where she was a faculty member between 2005 and 2012. She received her training as a pharmacist from Albert-Ludwigs-University in Freiburg, Germany, and her Master in Clinical Pharmacy and Ph.D. from the University of London, United Kingdom.

Tadataka (Tachi) Yamada, M.D., is a Venture Partner with Frazier Healthcare Partners. Prior to joining Frazier, he was Executive Vice-President, Chief Medical & Scientific Officer, and a board member of Takeda Pharmaceuticals. Dr. Yamada has served as President of the Bill & Melinda Gates Foundation Global Health Program. In this position, he oversaw grants totaling more than $9 billion in programs directed at applying technologies to address major health challenges of the developing world including tuberculosis, HIV, malaria and other infectious diseases, malnutrition, and maternal and child health. He was formerly Chairman, Research and Development and a Member of the Board of Directors of GlaxoSmithKline and before that was Chair of the Department of Internal Medicine and Physician-in-Chief at the University of Michigan Medical Center. Dr. Yamada holds a bachelor’s degree in history from Stanford University and obtained his M.D. from the New York University School of Medicine. In recognition of his contributions to medicine and science, he has been elected to membership in the National Academy of Medicine (United States), the Academy of Medical Sciences (UK), and the National Academy of Medicine (Mexico), and he has received an honorary appointment as Knight Commander of the Most Excellent Order of the British Empire (KBE). He is a Past-President of the Association of American Physicians and of the American Gastroenterological Association and he has served as a member of the President’s Council of Advisors on Science and Technology and the Advisory Committee to the Director of the National Institutes of Health. He is the Past Vice-Chair of the Council of the National Academy of Medicine and Chairman of the Board of Directors of the Clinton Health Access Initiative.